Clinical trial
Interfant-21 International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
NCT05327894 is registered in ClinicalTrials.gov with Princess Maxima Center for Pediatric Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Interfant-21 International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
- Lead sponsor
- Princess Maxima Center for Pediatric Oncology
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 15, 2022
- Completion date
- September 30, 2030
- Enrollment
- 160 (estimated)
- Sites
- 124
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoblastic leukemia, mixed phenotype acute leukemia